FDA Approves Three Novel HAE Therapies in 2025, Ending Four-Year Regulatory Drought
核心洞察
The FDA approved three novel hereditary angioedema (搜索) (HAE (搜索)) therapies in 2025 after four years without new approvals, increasing total marketed drugs by 38% to 11 products.
CSL Behring's garadacimab became the first FDA-approved drug targeting coagulation factor XII (搜索), offering a new biological mechanism for HAE (搜索) prevention.
KalVista's sebetralstat (Ekterly) represents the first oral on-demand treatment for HAE (搜索), providing patients with rapid relief during acute episodes.
The US Food and Drug Administration has transformed the hereditary angioedema (搜索) (HAE (搜索)) treatment landscape in 2025 with three groundbreaking approvals, ending a four-year regulatory drought that left patients waiting for novel therapeutic options. This surge of activity has increased the total number of marketed innovator drugs in the US by 38%, bringing the count to 11 products and introducing diverse treatment modalities that revolutionize HAE management.
HAE (搜索) is a potentially life-threatening inherited disease characterized by recurrent and severe episodes of swelling in various parts of the body, including the hands, feet, genitals, stomach, and face or throat, which can prove fatal. This rare condition affects approximately 7,000 people in the US.
First-in-Class Factor XII Inhibitor Breaks New Ground
CSL Behring achieved a significant milestone on June 16, 2025, when the FDA approved garadacimab, marking the first drug approval targeting coagulation factor XII (搜索). This represents a strategic advancement in HAE (搜索) treatment, as factor XII plays a major role in initiating the swelling cascade. By inhibiting this protein, garadacimab offers a direct mechanism to block the onset of attacks, representing a move towards earlier intervention in the disease pathway.
Oral On-Demand Treatment Offers New Flexibility
KalVista Pharmaceuticals secured FDA approval for sebetralstat (Ekterly) on July 3, 2025, introducing the second oral drug for HAE (搜索) with a unique administration approach. Unlike BioCryst's oral drug berotralstat hydrochloride, which requires daily prophylactic dosing, Ekterly is administered following the onset of symptoms, providing patients with the first oral on-demand treatment option. This approval represents a meaningful advancement in convenience and flexibility for patients requiring rapid and effective relief during acute episodes.
Antisense Technology Extends Dosing Intervals
The most recent approval came on August 21, 2025, when Ionis Pharma (搜索)'s donidalorsen sodium (搜索) became the first antisense oligonucleotide approved for HAE (搜索). This prophylactic treatment offers patients an extended dosing interval of every four to eight weeks, significantly longer than the every-two-week schedule required by other preventive therapies. The approval introduces a novel modality while potentially improving patients' quality of life through reduced dosing frequency.
Transforming Patient Care Options
The diversification of HAE (搜索) products provides patients with greater flexibility in terms of prophylactic and acute treatments, reducing the burden of the disorder and enabling patients to match treatment strategies to their individual lifestyles. Prior to 2025, FDA approvals in HAE were sparse, with only one approval each in 2017, 2018, and 2020, followed by complete regulatory silence from 2021 through 2024.
The three 2025 approvals have effectively reshaped the treatment landscape for HAE (搜索) patients in under nine months, introducing new mechanisms and modalities that broaden the treatment strategies available to this underserved patient population.